Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/162720
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Corominas, Héctor | - |
dc.contributor.author | Alegre, Cayetano | - |
dc.contributor.author | Narváez García, Francisco Javier | - |
dc.contributor.author | Fernández-Cid, Carlos Marras | - |
dc.contributor.author | Torrente Segarra, Vicenç | - |
dc.contributor.author | Gómez Rodríguez, Manuel | - |
dc.contributor.author | Maceiras Pan, Francisco | - |
dc.contributor.author | Morlà, Rosa | - |
dc.contributor.author | Martínez Rodríguez, Fernando José | - |
dc.contributor.author | Gómez-Centeno, Antoni | - |
dc.contributor.author | Losada Ares, Laura | - |
dc.contributor.author | Gonzalez Molina, Rocío | - |
dc.contributor.author | Paredes González-Albo, Silvia | - |
dc.contributor.author | Dalmau-Carolà, Joan | - |
dc.contributor.author | Pérez-García, Carolina | - |
dc.contributor.author | Barbazán Álvarez, Ceferino | - |
dc.contributor.author | Ercole, Liliana | - |
dc.contributor.author | Terrancle, Maria Ángeles | - |
dc.contributor.author | ACT-AXIS Study Group. | - |
dc.date.accessioned | 2020-05-27T20:50:48Z | - |
dc.date.available | 2020-05-27T20:50:48Z | - |
dc.date.issued | 2019-06-29 | - |
dc.identifier.issn | 0025-7974 | - |
dc.identifier.uri | http://hdl.handle.net/2445/162720 | - |
dc.description.abstract | To assess the hypothesis if tocilizumab (TCZ) is effective on disease activity, and also its effect in fatigue and other clinical and psychological disease-related factors in patients with rheumatoid arthritis (RA) treated with TCZ.A 24-week, multicenter, prospective, observational study in patients with moderate to severe RA receiving TCZ after failure or intolerance to disease-modifying antirheumatic drugs or tumor necrosis factor-alpha was conducted.Of the 122 patients included, 85 were evaluable for effectiveness (85% female, 51.9 ± 12.5 years, disease duration 8.7 ± 7.4 years). Mean change in C-reactive protein level from baseline to week 12 was -11.2 ± 4.0 (P < .001). Mean Disease Activity Index score (DAS28) decreased from 5.5 ± 1.0 at baseline to 2.7 ± 1.3 (P < .001) at week 24. Mean change in Functional Assessment of Chronic Illness Therapy score was -5.4 ± 11.2 points at week 24. Multiple regression analysis showed that the improvement in DAS28, sleep, and depression explained 56% and 47% of fatigue variance at week 12 and 24, respectively.Tocilizumab is effective in reducing disease activity and results in a clinically significant improvement in fatigue, pain, swollen joint count, morning stiffness, sleepiness, depression, and DAS28; the last 3 were specifically identified as factors explaining fatigue variance with the use of TCZ in RA patients. | - |
dc.format.extent | 8 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Lippincott, Williams & Wilkins. Wolters Kluwer Health | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.1097/MD.0000000000015947 | - |
dc.relation.ispartof | Medicine, 2019, vol. 98, num. 26, p. 15947 | - |
dc.relation.uri | https://doi.org/10.1097/MD.0000000000015947 | - |
dc.rights | cc-by (c) Corominas, Héctor et al., 2019 | - |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es | - |
dc.source | Articles publicats en revistes (Ciències Clíniques) | - |
dc.subject.classification | Fatiga | - |
dc.subject.classification | Artritis reumatoide | - |
dc.subject.classification | Farmacologia | - |
dc.subject.other | Fatigue | - |
dc.subject.other | Rheumatoid arthritis | - |
dc.subject.other | Pharmacology | - |
dc.title | Correlation of fatigue with other disease related and psychosocial factors in patients with rheumatoid arthritis treated with tocilizumab: ACT-AXIS study | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.identifier.idgrec | 692535 | - |
dc.date.updated | 2020-05-27T20:50:48Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 31261500 | - |
Appears in Collections: | Articles publicats en revistes (Ciències Clíniques) Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
692535.pdf | 394.2 kB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License